Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 8Lymphoma, Non-Hodgkin 7Recurrence 4Neoplasms 3Lymphoma, Large-Cell, Anaplastic 3Hodgkin Disease 2Hematologic Neoplasms 2Hematologic Diseases 2Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Carcinoma 1

Interventions

tazemetostat 2pembrolizumab 1interferon gamma-1b 1Rifampin 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Itraconazole 1Interferon-gamma 1Immunotherapy, Adoptive 1Immunotherapy 1Imatinib Mesylate 1Drug Therapy 1CLR1404 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Synovial × Rifampin × Lymphoid × Clear all
NCT04537715 2025-02-19

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

Ipsen

Phase 1 Completed
42 enrolled 39 charts
LymphoidOther hematologic neoplasmOther solid neoplasmSarcomaThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Sarcoma, Synovial, Lymphoma, Large B-Cell, Diffuse, Rhabdoid Tumor, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡